Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05845593 · ClinicalTrials.gov registry record
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
A clinical trial of Lupus Erythematosus, Systemic, sponsored by Ampel BioSolutions.
- Recruiting
- Registry status
- 200
- Enrollment target
- 11
- Study locations
NCT05845593: Recruiting study of Lupus Erythematosus, Systemic, sponsored by Ampel BioSolutions.
NCT05845593 is a study of Lupus Erythematosus, Systemic that is actively recruiting participants, run by Ampel BioSolutions. The registered enrollment target is 200 participants, roughly in line with the 196-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target. The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05845593, a study of Lupus Erythematosus, Systemic, is actively recruiting participants, sponsored by Ampel BioSolutions.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is an open label study to determine the association of the data obtained with LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE, including clinical involvement, SLEDAI score, Physician Global Assessment (PGA) and standard laboratory measures, including ANA, anti-DNA, anti-RNP and complement components C3 and C4, as well as Patient Reported Outcomes capturing pain, fatigue and Health-Related Quality of Life. The test will be administered on one occasion to patients with a clinical diagnosis of lupus or incomplete lupus and clinical and laboratory features evaluated contemporaneously. This trial includes a pilot study of approximately 10 subjects from 2-3 sites to assess whether the delivery times of LuGENE® laboratory results do not exceed more than 7 business days.
Conditions Studied
Interventions
- OTHER Decision Support Test
Study Locations (11)
California
- Cedars-Sinai Medical Center - Los Angeles
- Providence St. John's Health Center - Rheumatology - Santa Monica
New York
- Feinstein Institute for Medical Research - Manhasset
- The Hospital for Special Surgery - New York
Arizona
- Arizona Arthritis & Rheumatology Research, PLLC - Phoenix
Connecticut
- Yale School of Medicine - New Haven
Illinois
- Rush University Medical Center - Chicago
Maryland
- University of Maryland School of Medicine - Baltimore
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Arthritis and Osteoporosis Consultants of the Carolinas - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-12-19 |
| Est. Completion | 2025-03-05 |
What NCT05845593 shows while recruiting
NCT05845593 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 196-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target.
The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 1 intervention - of which Decision Support Test is the first listed.
NCT05845593 lists 11 locations in 9 states (California, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT05845593 about?
NCT05845593 is a clinical study titled "Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)". This is an open label study to determine the association of the data obtained with LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE, including clinical involvement, SLEDAI score, Physician Global Assessment (PGA) and standard laboratory measures, including...
What is the current status of trial NCT05845593?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-12-19. Estimated completion is 2025-03-05.
What conditions does trial NCT05845593 study?
This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.
What interventions are being tested in trial NCT05845593?
The interventions under investigation include: Decision Support Test (OTHER).
Who is sponsoring clinical trial NCT05845593?
This trial is sponsored by Ampel BioSolutions, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05845593 being conducted?
This trial has 11 study locations across Arizona, California, Connecticut, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Erythematosus, Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05845593's enrollment target sits among peer trials
200 12th of 29 higher than 17 of 29 other Lupus Erythematosus, Systemic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lupus Erythematosus, Systemic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
RECRUITING · Phase 3
-
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Trial of Belimumab in Early Lupus
RECRUITING · Phase 4
-
Dose Response of Exercise for Arthritis Management
RECRUITING · NA
-
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI